Research updates
On November 6, 2025, a Chinese phase 3 study of extended-release calcifediol (ERC) was presented as poster TH-PO1192 at ASN Kidney Week. NICOYA covered the study on WeChat on November 10.
The randomized, double-blind, placebo-controlled study enrolled 100 Chinese adults with stage 3 or 4 CKD, vitamin D insufficiency and secondary hyperparathyroidism (SHPT). The 26-week study assessed intact parathyroid hormone, total 25-hydroxyvitamin D and safety outcomes.
This research update does not provide individual treatment advice. Refer to locally approved prescribing information for eligible populations, limitations and safety information.
Reference: ASN Kidney Week 2025, TH-PO1192. DOI: 10.1681/ASN.202556rnsqhc.